Meanwhile, Herting et al. found that in small cell lung cancer (SCLC) patients (n = 32) treated with atezolizumab combined with carboplatin and etoposide, patients who experienced a reduction in central memory CD8+T cell (CD62L+ CD45RA-CD3+ CD8+T) after two treatment cycles had longer cumulative survival [95]. This evidence concerns the gene SELL and small cell lung carcinoma.